TScan Therapeutics Inc. (TCRX)
NASDAQ · Healthcare
TScan Therapeutics Inc. EBITDA 2020–2025
TScan Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- TScan Therapeutics Inc. annual ebitda for 2025 was -132.9 M, a 1.68% increase from 2024.
- TScan Therapeutics Inc. annual ebitda for 2024 was -130.7 M, a 48.45% increase from 2023.
- TScan Therapeutics Inc. annual ebitda for 2023 was -88.1 M, a 43.10% increase from 2022.
- TScan Therapeutics Inc. annual ebitda for 2022 was -61.5 M.
No data available.
TScan Therapeutics Inc. EBITDA — FAQ
TScan Therapeutics Inc. (TCRX) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TCRX's ebitda history?
The chart and table above show TScan Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.